{"success":true,"data":{"pressRelease":{"id":"3120","rtpr_id":"nBw84Rz27a","ticker":"BCYC","exchange":"NASDAQ","all_tickers":["BCYC"],"title":"Bicycle Therapeutics Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting","author":"Business Wire","published_at":"2026-04-21T14:31:00.079Z","article_body":"Bicycle Therapeutics Announces Oral and Poster Presentations at the 2026 ASCO\nAnnual Meeting\n\nBicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a\nnew and differentiated class of therapeutics based on its proprietary bicyclic\npeptide (Bicycle(®)) technology, today announced an oral presentation and\nmultiple poster presentations across five abstracts at the American Society of\nClinical Oncology (ASCO) 2026 Annual Meeting, taking place May 29–June 2 in\nChicago.\n\nPresentation Details:\n\nTitle: Interim analysis results from Duravelo-2: Zelenectide pevedotin (zele;\nBT8009) + pembrolizumab in patients (pts) with previously untreated locally\nadvanced/metastatic urothelial carcinoma (la/mUC)\n\nType: Rapid Oral Abstract Session\n\nSession: Genitourinary Cancer – Kidney and Bladder\n\nDate and Time: Monday, June 1, 8:30-8:36 a.m. CT\n\nAbstract Number: 4516\n\nLead Author: Yohann Loriot, M.D., Institute Gustave Roussy\n\nTitle: Interim analysis results from Duravelo-2: zelenectide pevedotin (zele;\nBT8009) in patients (pts) with previously treated locally advanced/metastatic\nurothelial carcinoma (la/mUC)\n\nType: Poster Session\n\nSession: Genitourinary Cancer – Kidney and Bladder\n\nDate and Time: Sunday, May 31, 9 a.m.-12 p.m. CT\n\nAbstract Number: 4566\n\nLead Author: Dan Petrylak, M.D., Yale School of Medicine\n\nTitle: Zelenectide pevedotin (BT8009) monotherapy in previously treated\nmetastatic urothelial carcinoma (mUC): Update on Duravelo-1\n\nType: Poster Session\n\nSession: Genitourinary Cancer – Kidney and Bladder\n\nDate and Time: Sunday, May 31, 9 a.m.-12 p.m. CT\n\nAbstract Number: 4563\n\nLead Author: Oscar Reig Torras, M.D., Hospital Clínic de Barcelona\n\nTitle: Zelenectide pevedotin (BT8009) plus pembrolizumab in 1L\ncisplatin-ineligible locally advanced/metastatic urothelial carcinoma: Update\non Duravelo-1 B7\n\nType: Poster Session\n\nSession: Genitourinary Cancer – Kidney and Bladder\n\nDate and Time: Sunday, May 31, 9 a.m.-12 p.m. CT\n\nAbstract Number: 4564\n\nLead Author: Ignacio Duran, M.D., Hospital Universitario Marqués de\nValdecilla\n\nTitle: Identify optimized dosage for zelenectide pevedotin in locally\nadvanced/metastatic urothelial carcinoma (la/mUC) using quantitative analyses\n\nType: Poster Session\n\nSession: Genitourinary Cancer – Kidney and Bladder\n\nDate and Time: Sunday, May 31, 9 a.m.-12 p.m. CT\n\nAbstract Number: 4567\n\nLead Author: Yasong Lu, Ph.D., Bicycle Therapeutics\n\nThe presentations will be made available in the Publications section of the\nBicycle Therapeutics website on the morning of each session.\n\nAbout Bicycle Therapeutics\n\nBicycle Therapeutics is a clinical-stage pharmaceutical company developing a\nnovel class of medicines, referred to as Bicycle(®) molecules, for diseases\nthat are underserved by existing therapeutics. Bicycle molecules are fully\nsynthetic short peptides constrained with small molecule scaffolds to form two\nloops that stabilize their structural geometry. This constraint facilitates\ntarget binding with high affinity and selectivity, making Bicycle molecules\nattractive candidates for drug development. The company is evaluating\nnuzefatide pevedotin, formerly BT5528, a Bicycle(®) Drug Conjugate (BDC(®))\ntargeting EphA2, a historically undruggable target; a pipeline of other\nbicycle-based conjugate molecules, including Bicycle(®) Radioconjugates\n(BRC(®)) for radiopharmaceutical use; zelenectide pevedotin (formerly\nBT8009), a BDC(®) targeting Nectin-4, a well-validated tumor antigen; BT7480,\na Bicycle Tumor-Targeted Immune Cell Agonist(®) (Bicycle TICA(®)) targeting\nNectin-4 and agonizing CD137; and, through various partnerships, is exploring\nthe use of Bicycle(®) technology to develop therapies for diseases in\nadditional therapeutic areas.\n\nBicycle Therapeutics is headquartered in Cambridge, UK, with many key\nfunctions and members of its leadership team located in Lexington, Mass. For\nmore information, visit bicycletherapeutics.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fbicycletherapeutics.com%2F&esheet=54519269&newsitemid=20260420659430&lan=en-US&anchor=bicycletherapeutics.com&index=1&md5=407505d01516b0e138fa4eb9330959ac)\n.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260420659430/en/\n(https://www.businesswire.com/news/home/20260420659430/en/)\n\nInvestors: \n\nMatthew DeYoung\n\nArgot Partners\n\nir@bicycletx.com \n(mailto:ir@bicycletx.com) \n212-600-1902\n\nMedia: \n\nArgot Partners\n\nmedia@bicycletx.com (mailto:media@bicycletx.com)\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw84Rz27a","title":"Bicycle Therapeutics Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting","author":"Business Wire","ticker":"BCYC","created":"2026-04-21T14:31:00.079Z","tickers":["BCYC"],"exchange":"NASDAQ","article_body":"Bicycle Therapeutics Announces Oral and Poster Presentations at the 2026 ASCO\nAnnual Meeting\n\nBicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a\nnew and differentiated class of therapeutics based on its proprietary bicyclic\npeptide (Bicycle(®)) technology, today announced an oral presentation and\nmultiple poster presentations across five abstracts at the American Society of\nClinical Oncology (ASCO) 2026 Annual Meeting, taking place May 29–June 2 in\nChicago.\n\nPresentation Details:\n\nTitle: Interim analysis results from Duravelo-2: Zelenectide pevedotin (zele;\nBT8009) + pembrolizumab in patients (pts) with previously untreated locally\nadvanced/metastatic urothelial carcinoma (la/mUC)\n\nType: Rapid Oral Abstract Session\n\nSession: Genitourinary Cancer – Kidney and Bladder\n\nDate and Time: Monday, June 1, 8:30-8:36 a.m. CT\n\nAbstract Number: 4516\n\nLead Author: Yohann Loriot, M.D., Institute Gustave Roussy\n\nTitle: Interim analysis results from Duravelo-2: zelenectide pevedotin (zele;\nBT8009) in patients (pts) with previously treated locally advanced/metastatic\nurothelial carcinoma (la/mUC)\n\nType: Poster Session\n\nSession: Genitourinary Cancer – Kidney and Bladder\n\nDate and Time: Sunday, May 31, 9 a.m.-12 p.m. CT\n\nAbstract Number: 4566\n\nLead Author: Dan Petrylak, M.D., Yale School of Medicine\n\nTitle: Zelenectide pevedotin (BT8009) monotherapy in previously treated\nmetastatic urothelial carcinoma (mUC): Update on Duravelo-1\n\nType: Poster Session\n\nSession: Genitourinary Cancer – Kidney and Bladder\n\nDate and Time: Sunday, May 31, 9 a.m.-12 p.m. CT\n\nAbstract Number: 4563\n\nLead Author: Oscar Reig Torras, M.D., Hospital Clínic de Barcelona\n\nTitle: Zelenectide pevedotin (BT8009) plus pembrolizumab in 1L\ncisplatin-ineligible locally advanced/metastatic urothelial carcinoma: Update\non Duravelo-1 B7\n\nType: Poster Session\n\nSession: Genitourinary Cancer – Kidney and Bladder\n\nDate and Time: Sunday, May 31, 9 a.m.-12 p.m. CT\n\nAbstract Number: 4564\n\nLead Author: Ignacio Duran, M.D., Hospital Universitario Marqués de\nValdecilla\n\nTitle: Identify optimized dosage for zelenectide pevedotin in locally\nadvanced/metastatic urothelial carcinoma (la/mUC) using quantitative analyses\n\nType: Poster Session\n\nSession: Genitourinary Cancer – Kidney and Bladder\n\nDate and Time: Sunday, May 31, 9 a.m.-12 p.m. CT\n\nAbstract Number: 4567\n\nLead Author: Yasong Lu, Ph.D., Bicycle Therapeutics\n\nThe presentations will be made available in the Publications section of the\nBicycle Therapeutics website on the morning of each session.\n\nAbout Bicycle Therapeutics\n\nBicycle Therapeutics is a clinical-stage pharmaceutical company developing a\nnovel class of medicines, referred to as Bicycle(®) molecules, for diseases\nthat are underserved by existing therapeutics. Bicycle molecules are fully\nsynthetic short peptides constrained with small molecule scaffolds to form two\nloops that stabilize their structural geometry. This constraint facilitates\ntarget binding with high affinity and selectivity, making Bicycle molecules\nattractive candidates for drug development. The company is evaluating\nnuzefatide pevedotin, formerly BT5528, a Bicycle(®) Drug Conjugate (BDC(®))\ntargeting EphA2, a historically undruggable target; a pipeline of other\nbicycle-based conjugate molecules, including Bicycle(®) Radioconjugates\n(BRC(®)) for radiopharmaceutical use; zelenectide pevedotin (formerly\nBT8009), a BDC(®) targeting Nectin-4, a well-validated tumor antigen; BT7480,\na Bicycle Tumor-Targeted Immune Cell Agonist(®) (Bicycle TICA(®)) targeting\nNectin-4 and agonizing CD137; and, through various partnerships, is exploring\nthe use of Bicycle(®) technology to develop therapies for diseases in\nadditional therapeutic areas.\n\nBicycle Therapeutics is headquartered in Cambridge, UK, with many key\nfunctions and members of its leadership team located in Lexington, Mass. For\nmore information, visit bicycletherapeutics.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fbicycletherapeutics.com%2F&esheet=54519269&newsitemid=20260420659430&lan=en-US&anchor=bicycletherapeutics.com&index=1&md5=407505d01516b0e138fa4eb9330959ac)\n.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260420659430/en/\n(https://www.businesswire.com/news/home/20260420659430/en/)\n\nInvestors: \n\nMatthew DeYoung\n\nArgot Partners\n\nir@bicycletx.com \n(mailto:ir@bicycletx.com) \n212-600-1902\n\nMedia: \n\nArgot Partners\n\nmedia@bicycletx.com (mailto:media@bicycletx.com)\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-04-21T14:31:00.127982245Z","server_sent_at_ms":1776781860127},"received_at":"2026-04-21T14:31:00.184Z","source_url":"https://www.businesswire.com/news/home/20260420659430/en/"},"analysis":{"id":"2053","press_release_id":"3120","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"clinical_trial","narrative":"Bicycle Therapeutics announced it will present data from five abstracts at the ASCO 2026 Annual Meeting, focusing on its lead asset zelenectide pevedotin.\n\nThe presentations include an oral session on interim results from the Duravelo-2 study combining zelenectide pevedotin with pembrolizumab in first-line urothelial carcinoma.\n\nAdditional posters will cover monotherapy data from Duravelo-1, updates on cisplatin-ineligible patients, and optimized dosage analyses.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Standard conference participation notice pending actual data readout."},"keyFigures":{"customDimensions":{"asco_abstract_count":5}},"quotedText":"","namedEntities":{"people":[{"name":"Yohann Loriot, M.D.","role":"Lead Author, Abstract 4516"},{"name":"Dan Petrylak, M.D.","role":"Lead Author, Abstract 4566"},{"name":"Oscar Reig Torras, M.D.","role":"Lead Author, Abstract 4563"},{"name":"Ignacio Duran, M.D.","role":"Lead Author, Abstract 4564"},{"name":"Yasong Lu, Ph.D.","role":"Lead Author, Abstract 4567"},{"name":"Matthew DeYoung","role":"Investor Contact, Argot Partners"}],"products":["Zelenectide pevedotin (zele; BT8009)","pembrolizumab","Nuzefatide pevedotin (BT5528)","BT7480"],"companies":[{"name":"Bicycle Therapeutics plc","ticker":"BCYC"},{"name":"Argot Partners","relationship":"IR/PR firm"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"This is a standard announcement of upcoming conference presentations for interim trial data. While ASCO is a major conference, the release itself does not contain clinical outcomes or efficacy data, only the scheduling of data presentation."},"tickerRelevance":{"others":[],"primary":"BCYC"},"eventTypeSecondary":[]},"event_type":"clinical_trial","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Bicycle Therapeutics announced it will present data from five abstracts at the ASCO 2026 Annual Meeting, focusing on its lead asset zelenectide pevedotin.\n\nThe presentations include an oral session on interim results from the Duravelo-2 study combining zelenectide pevedotin with pembrolizumab in first-line urothelial carcinoma.\n\nAdditional posters will cover monotherapy data from Duravelo-1, updates on cisplatin-ineligible patients, and optimized dosage analyses.","key_figures":{"customDimensions":{"asco_abstract_count":5}},"named_entities":{"people":[{"name":"Yohann Loriot, M.D.","role":"Lead Author, Abstract 4516"},{"name":"Dan Petrylak, M.D.","role":"Lead Author, Abstract 4566"},{"name":"Oscar Reig Torras, M.D.","role":"Lead Author, Abstract 4563"},{"name":"Ignacio Duran, M.D.","role":"Lead Author, Abstract 4564"},{"name":"Yasong Lu, Ph.D.","role":"Lead Author, Abstract 4567"},{"name":"Matthew DeYoung","role":"Investor Contact, Argot Partners"}],"products":["Zelenectide pevedotin (zele; BT8009)","pembrolizumab","Nuzefatide pevedotin (BT5528)","BT7480"],"companies":[{"name":"Bicycle Therapeutics plc","ticker":"BCYC"},{"name":"Argot Partners","relationship":"IR/PR firm"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:2f2748f0fcc8c4f2","schema_hash":"sha256:ad96b863d7123008","created_at":"2026-04-21T20:22:24.981Z","global_importance":3,"audience_relevance":3,"importance_components":{"method":"backfill-heuristic","signals":{"bodyLong":false,"headlineTier1":false,"tickerCovered":false,"hadSignificance":false},"version":1,"computedAt":"2026-04-27T11:52:53.575Z"}},"durationMs":29267,"modelName":"glm-4.7"}}